Tackling treatment toxicity

Christopher PennellChristopher Pennell, Ph.D., part of the U’s laboratory medicine and pathology faculty, is trying to train the body’s natural defense system to attack cancerous cells.

Pennell is studying a breakthrough treatment called chimeric antigen receptor (CAR) therapy. It involves isolating the patient’s white blood cells, reprogramming them to recognize cancerous cells in the blood, and then injecting them back into the patient to kill those cells.

Although CAR therapy has proved effective for patients with B-cell acute lymphoblastic leukemia, it can also have life-threatening side effects.

“We don’t know why CAR therapy has these effects on some patients and not others,” he says. “We can’t predict or prevent it.”

Support from Minnesota Masonic Charities is allowing Pennell and his team to study the toxicity problem.

He says their biggest accomplishment so far is the development of a mouse model that replicates CAR therapy’s antitumor effects and toxicities. “Because we designed our mice to have human components, the most promising new CARs eventually may be able to go directly to patients without further modifications.”

“Masonic support provides me with the freedom to pursue outside-of-the-box approaches that have paid off.”

Related

Sloan Featured
With Masonic Scholar support, Lindsey Sloan, radiation oncology faculty member and one of the University’s newest recruits, is dedicating her work in... Read more
Erickson featured
Clear cell ovarian cancer (CCOC) is a subtype of ovarian cancer with high rates of recurrence and resistance to chemotherapy.
Julie Ostrander
Proteins play an essential role in regulating how the human body functions. But sometimes they stop working as they should, causing cells to grow out... Read more